NTT
15.5.2020 08:02:11 CEST | Business Wire | Press release
NTT Corporation (NTT, President & CEO: Jun Sawada) concluded a Cooperation Agreement on the ITER Project with the ITER International Fusion Energy Organization (ITER Organization).
By supporting the ITER Project, which has the objective of building the world’s first experimental hydrogen fusion reactor, NTT will accelerate “Development of innovative environment and energy technologies”, and contribute to the reduction of the environmental impact of customers, companies and society.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005951/en/
1. Background
The ITER Project is an extraordinarily large international project that has the objective of building the world’s first experimental hydrogen fusion reactor (ITER) to prove the scientific and technical feasibility of the fusion energy for peaceful purposes. The ITER Organization, an international organization with seven members – Japan, the European Union, Russia, the United States, South Korea, China, and India – is engaged in the ITER Project.
NTT is aiming at “Zero Environmental Impact” by supporting customers, enterprises, and society in reducing their impact on the environment through our R&D aimed at creating innovations that break through conventional limitations and by pursuing business activities designed to decrease deleterious effects on the environment. For example, NTT is preparing to establish the Space Environment and Energy Laboratories, which will undertake research with the goal of creating innovative energy and environmental technologies.
NTT assumes the use of photonic technologies developed for IOWN* concept, and will work to extend the current ICT technologies, which would benefit the ITER Project.
*IOWN (Innovative Optical and Wireless Network) is a future communications infrastructure to create a smarter world by using cutting-edge technologies like photonics and computing technologies.
https://www.rd.ntt/e/iown/
2. Scope of Cooperation
Under the strategic intent of this Cooperation Agreement, NTT will collaborate in the following areas.
- Exploration of innovative future Information and Communication Technology, including ultra-high-speed network, ultra-low latency network connectivity, data storage, computing, and global network infrastructure.
- Exploration of the concept “IOWN” including All-Photonics Network, Digital Twin Computing, and Cognitive Foundation.
This is the first time that the ITER Organization has signed a Long Term Non-Commercial Cooperation Agreement with a private Japanese company. As a general ICT player capable of providing full-stack, full-lifecycle services on a global scale, the NTT Group will collaborate on information distribution and control platforms in preparation for ITER’s first plasma in 2025 and beyond.
NTT will work out the details and conclude an implementation agreement.
3. Executive statements
“With an aim of achieving zero environmental impact, NTT is conducting R&D to create the innovations needed to achieve this goal, and carrying out its business activities in a manner that reduces its effects on the environment. Safe and permanent fusion energy is one of the most promising technologies in this important endeavor. We believe that NTT’s groundbreaking R&D activities, including IOWN, and our ability to construct global infrastructure can make a valuable contribution to the ITER Organization, a leading research entity in this area. Under this agreement, we will work closely with the ITER Organization to demonstrate the feasibility of fusion power at an industrial scale for the first time in human history.”
-Jun Sawada
, President & CEO, NTT
“We, with the seven ITER Members, believe that fusion power can become a clean and safe vital contributor to the global energy mix for our civilization starting in this century for numerous millennium, and the progress of the ITER Project is essential for that path. I am pleased to have global ICT companies like NTT as one of our long-term non-commercial collaboration partners, with the solid capacity to develop advanced global ICT technologies as well as the capability to envision innovative future technologies strategies such as the IOWN concept that fusion will definitively need.”
-Bernard Bigot
, Director-General, the ITER Organization
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005951/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
